NCT03488628Completed
High-Flow Nasal Oxygen Therapy for Exacerbation of Chronic Pulmonary Obstructive Disease.
High-Flow Nasal Oxygen Therapy for Exacerbation of Chronic Pulmonary Obstructive Disease: A Randomized, Open-label, Single-center, Pilot Study.
Source: ClinicalTrials.gov · Last updated 24 Dec 2025
Brief summary (registry, in English)
High-Flow Nasal Oxygen (HFNO) therapy has never been tested against Noninvasive ventilation, the reference standard therapy for acute exacerbation of chronic obstructive pulmonary disease (COPD), in randomized clinical trials. The aim of the present study is to compare the effects of HFNO therapy on arterial blood gas variables over the first 24 hours of therapy, to those of Noninvasive ventilation, in patients experiencing a moderate (i.e. with arterial pH within 7.25-7.35) exacerbation of COPD.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 51 (actual)
- First submitted
- 26 Mar 2018
- Start date
- 27 Jun 2018
- Primary completion date
- 3 Oct 2025
- Lead sponsor
- Centre Hospitalier Régional d'Orléans
- Diseases
- COPD
- NCT number
- NCT03488628
What you commit to
- Study type: Interventional
- Participants enrolled: 51
- From 27 Jun 2018 to the primary completion date, 3 Oct 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Contraindication to aither Noninvasive ventilation or to High-Flow Nasal Oxygen therapy
- Previous inclusion in the study
Other illness
- Known sleep apnea syndrome
Age
- Age below 18
Other
- Pregnancy
- Patent treated by noninvasive ventilation at home
- Not affiliated to French scial security
Who the study is looking for
- Age \> 18
- Known Chronic Obstructive Pulmonary disease (COPD)
- respiratory rate or presence of accessory respiratory muscles activity on physical exam
- moderate exacerbation of COPD as defined by an arteria pH between 7.25 and 7.35 and an arterial carbon dioxide partial pressure (PaCO2) equal or above 45 mm Hg
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| CHR d'Orléans Coordinator of this site? Confirm its status | Orléans | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.